|
| Classes | Regimens | Advantages | Disadvantages | References |
|
| Trastuzumab + Doxorubicin + Cyclophosphamide | Improved RR, PFS, and OS | Cardiomyopathy, hematologic toxicity | [41, 42] |
| Trastuzumab + Epirubicin + Cyclophosphamide |
| mAb based | Trastuzumab + other chemotherapy (Paclitaxel, Docetaxel, Vinorelbine, Capecitabine, Platinum compounds, and Gemcitabine) | Improved RR and PFS | Increased hematologic toxicity | [43] |
| Bevacizumab + Paclitaxel | Improved PFS | More toxicity (hypertension, proteinuria, bleeding, nasal septum perforation, thromboembolic event, heart failure, mortality) | [44] |
| Cetuximab + Cisplatin | Improved RR and PFS in patients with TNBC | More acne-like rash, neutropenia, dyspnea | [38] |
|
| Lapatinib + Capecitabine | | | |
| Lapatinib + Paclitaxel | Improved RR, TTP, PFS | More toxicity (toxicity from chemotherapy plus diarrhea, skin rash, nausea, pruritis) | [45–47] |
| Tyrosine kinase inhibitor based | Lapatinib + Letrozole | | | |
| Sunitinib + Docetaxel | No worsen toxicity | Nonsignificant combination activity | [48] |
| Erotinib + Cisplatin + Gemcitabine | Well tolerated | No survival benefit | [49] |
|
| PARP inhibitor based | Iniparib + Gemcitabine + Carboplatin | Improved PFS and OS | Neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia | [50] |
| Olaparib + Gemcitabine + Carboplatin | Improved RR | | [51] |
|
| Multiple targeted | Trastuzumab + Lapatinib | Improved PFS and Overcome TRZ resistance | Additive toxicity from TRZ and Lapatinib, patient compliance issue (IV and oral administration) | [52] |
|
